Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-07-06 22:44 |
Cellectis annonce la suspension de l’étude clinique MELANI-01
|
French | 71.1 KB | ||
| 2020-07-06 22:33 |
Cellectis Reports Clinical Hold Placed on MELANI-01 Study
|
English | 92.5 KB | ||
| 2020-06-29 22:30 |
Résultats de l’Assemblée Générale Mixte des Actionnaires de Cellectis S.A. du 2…
|
French | 73.9 KB | ||
| 2020-06-29 22:30 |
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held o…
|
English | 80.8 KB | ||
| 2020-06-25 22:30 |
Cellectis publie une méthode de fabrication simplifiée pour générer des thérapi…
|
French | 68.6 KB | ||
| 2020-06-25 22:30 |
Cellectis Published Streamlined Manufacturing Method to Generate Ultrapure Allo…
|
English | 101.3 KB | ||
| 2020-03-04 22:30 |
Informations privilégiées / Autres communiqués
|
French | 430.1 KB | ||
| 2020-03-04 22:30 |
Inside Information / Other news releases
|
English | 359.7 KB | ||
| 2020-03-04 22:05 |
Informations privilégiées / Autres communiqués
|
French | 116.6 KB | ||
| 2020-03-04 22:05 |
Inside Information / Other news releases
|
English | 90.1 KB | ||
| 2020-02-25 22:30 |
Inside Information / Other news releases
|
English | 145.5 KB | ||
| 2020-02-25 22:30 |
Informations privilégiées / Autres communiqués
|
French | 132.8 KB | ||
| 2020-02-18 22:30 |
Informations privilégiées / Autres communiqués
|
French | 173.7 KB | ||
| 2020-02-18 22:30 |
Inside Information / Other news releases
|
English | 140.7 KB | ||
| 2020-02-07 23:00 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 63.8 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
